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Abstract
Background: Depression Care for People with Cancer is a complex intervention delivered by specially trained cancer nurses, under
the supervision of a psychiatrist. It is given as a supplement to the usual care for depression, which patients receive from their
general practitioner and cancer service. In a 'proof of concept' trial (Symptom Management Research Trials in Oncology-1)
Depression Care for People with Cancer improved depression more than usual care alone. The second Symptom Management
Research Trial in Oncology (SMaRT Oncology-2 Trial) will test its effectiveness and cost-effectiveness in a 'real world' setting.
Design: A two arm parallel group multi-centre randomised controlled trial.
Trial Procedures: 500 patients will be recruited through established systematic Symptom Monitoring Services, which screen
patients for depression. Patients will have: a diagnosis of cancer (of various types); an estimated life expectancy of twelve months
or more and a diagnosis of Major Depressive Disorder. Patients will be randomised to usual care or usual care plus Depression
Care for People with Cancer. Randomisation will be carried out by telephoning a secure computerised central randomisation
system or by using a secure web interface. The primary outcome measure is 'treatment response' measured at 24 week outcome
data collection. 'Treatment response' will be defined as a reduction of 50% or more in the patient's baseline depression score,
measured using the 20-item Symptom Checklist (SCL-20D). Secondary outcomes include remission of major depressive
disorder, depression severity and patients' self-rated improvement of depression.
Trial Registration: Current controlled trials ISRCTN40568538
Trial Hypotheses: (1) Depression Care for People with Cancer as a supplement to usual care will be more effective than usual
care alone in achieving a 50% reduction in baseline SCL-20D score at 24 weeks. (2) Depression Care for People with Cancer as a
supplement to usual care will cost more than usual care alone but will be more cost effective in achieving improvements in
patients' depression and quality of life.
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Background
When depression complicates medical conditions, it is
associated with substantially reduced quality of life [1].
Patients also experience increased symptom burden and
greater disability, and are less likely to adhere to medical
treatments [2]. Although depression is common in
patients who have cancer, it is frequently undetected and
untreated [3].
Depression Care for People with Cancer is a complex inter-
vention delivered by specially trained Care Managers (for
the SMaRT Oncology-2 Trial these will be cancer nurses)
supervised by a psychiatrist, which will supplement usual
care. It is based on the 'collaborative care' model of
depression management developed by the Seattle group
[4-6], adapted for patients with cancer and a specialist set-
ting.
Recent meta-analyses have found that interventions based
on the 'collaborative care' model were more effective in
improving depression outcomes than standard care for
patients in primary care [7,8]. However, few trials have
specifically included patients with co-morbid medical ill-
nesses. Trials in patients with diabetes [9] and in older
patients with various co-morbidities [6] have reported
modest effects. A pilot study of collaborative care in low-
income Latinas with co-morbid depression and cancer
reported promising initial results [10].
Depression Care for People with Cancer has been found to be
feasible to deliver [11] and the SMaRT oncology-1 'proof-
of-concept' trial found that patients who received the
intervention had significantly better outcomes than those
who received usual care alone at three months (standard-
ised effect size of 0.43) and that this difference was sus-
tained at six and twelve months [12]. We now propose to
evaluate the effectiveness and cost-effectiveness of this
complex intervention in a large pragmatic multi-centre
randomised controlled trial.
Methods
Design
A two-arm parallel group, multi-centre, randomised con-
trolled trial with outcome data collection every 12 weeks
to 48 weeks post-randomisation.
Patients
500 patients will be recruited from selected oncology out-
patient clinics in NHS Lothian and NHS Greater Glasgow
and Clyde.
To be included in the trial patients must:
• Have a diagnosis of cancer, with active disease within
the last five years.
￿ Be aged 18 or over.
￿ Be attending a specialist oncology clinic.
￿ Have a predicted survival, estimated by their cancer spe-
cialist, of twelve months or more.
￿ Have symptoms which meet DSMIV criteria for Major
Depressive Disorder (MDD), using the inclusive approach
to diagnosis with the current Major Depressive Episode
(MDE) having being present for four weeks or more.
Patients will be excluded if:
￿ They are unable to provide informed consent to partici-
pate.
￿ The episode of depression is chronic (defined as a his-
tory of continuous depression for at least two years).
￿ They are judged to require urgent psychiatric care.
￿ They are receiving active psychiatric or psychological
treatment from specialist mental health services.
￿ They have cognitive impairment or communication dif-
ficulties (including inability to adequately understand
verbal explanations or written information in English)
which are incompatible with the intervention.
￿ They have known cerebral metastases.
￿ They are unable to attend regularly for treatment ses-
sions.
￿ The intervention is judged to be inappropriate due to a
medical condition which requires alternative treatment.
￿ The intervention is judged to be inappropriate due to a
psychiatric condition which requires alternative treatment
(psychotic illness, bipolar affective disorder, obsessive
compulsive disorder, substance abuse or dependence).
￿ Their participation in the trial is judged to be inappro-
priate on other clinical grounds.
N.B Patients receiving active cancer treatments will not be
excluded unless they fulfil one or more of the exclusion
criteria listed above.
Patient identification and enrolment
In order to obtain a representative sample, patients will be
identified through the Symptom Monitoring Service
(SMS) in selected oncology outpatient clinics of NHS
Lothian and NHS Greater Glasgow and Clyde.Trials 2009, 10:18 http://www.trialsjournal.com/content/10/1/18
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The SMS is part of the routine NHS care for patients
attending these clinics. It comprises two stages:
￿ Stage 1 Patients complete self-report questionnaires in
the clinic to evaluate their symptoms, including emo-
tional distress (Hospital Anxiety and Depression Scale,
HADS). A summary of each patient's symptoms is gener-
ated for their oncology team.
￿ Stage 2 Patients with high emotional distress scores
(HADS total score of 15 or more) receive a brief tele-
phone-delivered, depression screening interview adminis-
tered by trained staff (graduate research assistants). The
interview comprises the major depression component of
the Structured Clinical Interview for DSMIV (SCID).
When clinically relevant, a report is generated for the
patient's general practitioner (GP) and oncologist. The
SMS staff will ask patients, with an MDE of at least four
weeks duration and a cancer prognosis of twelve months
or more, to give permission for the research team to con-
tact them. It will be made clear that patients who do so
will not be obliged to participate in the trial.
Once patients have given permission, the research team
provide them with a trial information leaflet (usually by
post) and will contact them directly (usually by tele-
phone). Patients will be informed, during the telephone
call, that if they are interested in taking part, their suitabil-
ity for inclusion in the trial must first be assessed. Infor-
mation will be required from patients' medical records in
order to achieve this.
Patients will therefore be asked, at this stage, to give verbal
consent for the research team to access their medical
records. This will minimise the burden on patients of
unnecessary face-to-face assessments. Consent to access
medical records is required as the researchers do not pro-
vide the patient's usual clinical care. The patient's records
will be used to determine the presence or absence of spe-
cific inclusion and exclusion criteria, before they are seen
for a face-to-face assessment (if appropriate). If the patient
does not give consent for the research team to access their
records at this stage, consent for this will be obtained dur-
ing the face-to-face assessment.
At the face-to-face assessment, patients will be given a full
explanation of the two treatment conditions and of the
procedures for randomised allocation to these and for
outcome data collection. Written informed consent will
then be obtained from patients for the eligibility assess-
ment and, if appropriate, trial participation. Patients will
be asked to consent to the information gathered about
them being retained even if they are found to be ineligible
to participate in the trial. This information will be used to
inform an estimate of the generalisability of the trial find-
ings.
The information retained from medical records and the
face-to-face assessment will be used to determine eligibil-
ity. Eligibility assessments will be carried out by trained
research staff (senior nurses, psychologists and psychia-
trists) and will include administration of the major
depression component of the Structured Clinical Inter-
view for DSMIV (SCID) to confirm the patient's diagnosis
of major depression. If the patient is eligible to partici-
pate, their willingness to do so will be confirmed before
randomisation. The patient's details will be entered into a
database via an automated telephone service or secure
website. The patient's treatment allocation will be auto-
matically generated. The research team will inform the
patient of their allocation either face-to-face or by tele-
phone.
At all stages the research team will endeavour to record
reasons for non-participation.
Trial treatment – comparison (usual care)
The patient's GP and oncologist will be informed of their
diagnosis of MDD. Patients will receive the usual clinical
management for their depression. Data will be collected
from all patients to allow a retrospective description of the
'usual care' that they receive.
Trial treatment – intervention (usual care supplemented 
with Depression Care for People with Cancer)
In addition to the usual care described above, patients
allocated to the condition will receive Depression Care for
People with Cancer. This will be delivered by specially
trained Care Managers (cancer nurses) under the supervi-
sion of the SMaRT Psychiatry team. Patients will be allo-
cated to Care Managers systematically, by being allocated
to the next Care Manager on the appropriate site-specific
list. If the allocated Care Manager is unable to see the
patient for their first treatment session within two weeks
(e.g. due to leave or staff sickness), the patient will be allo-
cated to the next listed Care Manager.
The intervention is described in detail in the Depression
Care for People with Cancer Treatment Manual and com-
prises two phases:
(a) Treatment Phase: patients will be offered a maximum
of ten 30–45 minute sessions with their Care Manager
over a 16 week period (patients are expected to receive an
average of six to eight sessions).
(b) Maintenance phase: patients will then receive active
treatment follow-up by telephone every four weeks until
the end of their participation in the trial.Trials 2009, 10:18 http://www.trialsjournal.com/content/10/1/18
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During the Treatment Phase the patient's Care Manager
will: (a) coordinate their depression care by liaising with
all relevant health professionals; (b) monitor their symp-
toms of depression, using a brief standardised depression
questionnaire (Patient Health Questionnaire-9, PHQ-9)
at each session; (c) provide a brief psychological interven-
tion comprising education about depression and its man-
agement (including the use of antidepressant medication,
being active and coping with problems better) and Prob-
lem Solving Treatment. Where possible, treatment ses-
sions will be delivered at the cancer clinics of NHS
Lothian and NHS Greater Glasgow and Clyde. Treatment
sessions will be delivered at home or by telephone for
patients who are unable to attend the hospital.
During the Maintenance Phase patients will be asked to
complete the PHQ-9 at monthly follow-up telephone
calls. Patients' responses to this questionnaire will be
reviewed by their Care Manager and appropriate action
will be taken as necessary. Follow-up telephone calls will
be administered by an Interactive Voice Response (IVR)
computerised telephone system or by the Care Manager
for patients who are unable or unwilling to use the sys-
tem. Patients will be given a full explanation of the follow-
up procedure (including how to use the IVR system when
appropriate) during the Treatment Phase.
All patients will be discussed during weekly supervision
sessions for Care Managers, provided by the SMaRT Psy-
chiatry Team. In addition, a member of the Psychiatry
Team will be available to respond to emergencies. At any
stage of treatment patients who report suicidal thoughts
will be discussed with the Psychiatry Team and an appro-
priate management plan implemented. A supervising psy-
chiatrist will review all patients who in their opinion: (a)
require a diagnostic re-assessment; (b) have failed to
achieve a treatment response (defined as a 50% drop in
their PHQ-9 score and a PHQ-9 score of <10) by session
five or week eight of the Treatment Phase (whichever is
earlier); (c) require assessment for referral to general adult
psychiatric care (patients with high suicide risk, psychosis
or mania and those requiring inpatient care).
Patients' adherence to the intervention will be monitored
by recording their attendance at treatment sessions, com-
pletion of homework, antidepressant prescription (drug
and dose) and self-reported compliance with medication.
In order to ensure Care Manager's compliance with the
treatment manual, all treatment sessions (of patients who
consent to this) will be digitally video or audio recorded.
Recordings and treatment notes will be reviewed regularly
by the SMaRT Psychiatry Team and a randomly selected
10% sample of recordings will be independently reviewed
and rated on a standardised adherence checklist, designed
specifically for this intervention.
Primary outcome measure
The primary outcome measure is 'treatment response'
measured at 24 week outcome data collection. 'Treatment
response' will be defined as a reduction of 50% or more in
the patient's baseline SCL-20D score. A binary primary
outcome was chosen as this is a pragmatic trial and an
outcome of clear clinical relevance is therefore required.
Secondary outcome measures
The following secondary outcome measures will be
assessed:
￿ Remission of major depressive disorder, defined as an
SCL-20D score of < 0.75 at 24 and 36 and 48 weeks
(higher than in primary care trials, to allow for cancer-
related somatic symptoms).
￿ Depression severity, defined for each patient as the aver-
age of their SCL-20D score at 24, 36 and 48 weeks.
￿ Patient's self-rated improvement of depression, meas-
ured by a five point global improvement scale.
Tertiary outcome measures
The following tertiary outcome measures will be assessed
at 12, 24, 36, and 48 weeks from randomisation:
￿ Severity of depression symptoms, measured by the SCL-
20D.
￿ Remission of major depressive disorder, defined as an
SCL-20D score of < 0.75.
￿ Remission of major depressive disorder, defined as an
SCL-20D score of < 0.5.
￿ Severity of anxiety symptoms, measured by the SCL-
10A.
￿ Severity of pain and fatigue, measured by the relevant
symptom scales of the EORTC QLQ-C30.
￿ Physical, social and role functioning, and overall health
and quality of life measured by the relevant scales of the
EORTC QLQ-C30.
￿ Patient's satisfaction with care, measured by a 5-point
Likert scale item developed specifically for the trial.
Measures of cost and health-related quality of life
The following economic outcome measures will be
assessed at 12, 24, 36 and 48 weeks from randomisation:Trials 2009, 10:18 http://www.trialsjournal.com/content/10/1/18
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￿ Cost of 'usual care' treatments received for depression.
￿ Cost of health care service use (primary, secondary and
community based).
￿ Cost of the trial intervention.
￿ Health related quality of life, measured by EQ-5D.
Data collection
Baseline data will be obtained by the assessor at the end
of the face-to-face eligibility assessment as near as possible
prior to randomisation
Outcome data collection will be obtained by a dedicated
team who are blind to group allocation and are situated
and managed independently from the trial team. This
team will be managed by the Scottish Mental Health
Research Network (SMHRN). Outcome data will be col-
lected at 12, 24, 36 and 48 weeks from randomisation.
All baseline and outcome data will be collected using self-
report questionnaires sent by mail with telephone calls or
face-to-face interviews to collect missing items or whole
questionnaires in order to maximise response rate. The
date of completion of all questionnaires will be noted.
Data collection will aim to be within one week either side
of the specified follow-up date.
Data collection instruments
The following data will be collected from patients at base-
line, 12, 24, 36 and 48 weeks
￿ Symptom Checklist Depression Scale (SCL-20D)
￿ Symptom Checklist Anxiety Scale (SCL-10A)
￿ European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
￿ Patient's satisfaction with depression care (question
developed specifically for the trial)
￿ EuroQol-5D (EQ-5D)
￿ Treatments received for depression (measures devel-
oped specifically for the trial)
￿ Use of health care services (measures developed specifi-
cally for the trial)
At baseline, demographic details and information about
the patient's cancer will also be collected.
Sample size
The power calculation is based on the primary outcome
measure, namely 'treatment response' defined as a reduc-
tion of 50% or more in baseline SCL-20D score at 24
weeks. Two treatment groups of 240 patients (i.e. 480 in
total) will give 90% power to detect an increase in the
response rate from 35% to 50% at the 5% significance
level, and 80% power to detect an increase in the response
rate from 35% to 48% at the 5% significance level. Target-
ing recruitment at a total of 500 patients allows for a 4%
loss to follow up at six months. This loss to follow-up rate
is comparable with that achieved in the recently com-
pleted efficacy trial.
Method of randomisation
In order to ensure similarity in the baseline characteristics
of the two treatment groups, randomisation will be car-
ried out using a combination of stratification and minimi-
sation. Stratification will be by trial centre (Edinburgh,
Glasgow) and minimisation variables will be age (≤50,
51–60, >60), cancer type (breast, genito-urinary, gynaeco-
logical, other) and sex. The minimisation variables are all
equally weighted and will be balanced within each centre
according to a deterministic algorithm. When the two
treatment arms are perfectly balanced in terms of the age,
cancer type and gender characteristics of a new subject,
treatment allocation will occur randomly with equal
probability assigned to the two treatments. The randomi-
sation system is maintained by the Division of Clinical
Neuroscience (DCN) Clinical Trials Unit at the University
of Edinburgh, and allows for the real-time randomisation
of patients using either a telephone (IVR) or web-based
user interface.
Statistical analyses
A single main analysis will be performed at the end of the
trial when all outcome data have been collected. An inde-
pendent Data Monitoring Committee will review confi-
dential interim analyses of accumulating data at least
annually. A detailed Statistical Analysis Plan will be devel-
oped prior to closure of the trial database and prior to the
unblinding of the treatment allocations. The main analy-
ses will be performed blind to treatment allocation on the
'intention-to-treat' principle, incorporating all ran-
domised patients with usable outcome data.
The primary outcome measure of treatment response at
24 weeks will be analysed using logistic regression, with
the minimisation variables being included as covariates.
The results will be reported as an adjusted odds ratio with
its corresponding 95% confidence interval.
The secondary outcome measure of remission of major
depressive disorder at each and all of 24, 36 and 48 weeksTrials 2009, 10:18 http://www.trialsjournal.com/content/10/1/18
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will be analysed in the same way as the primary outcome
measure.
The secondary outcome measure of depression severity
averaged over 24, 36 and 48 weeks will be analysed using
analysis of covariance, with the baseline SCL-20D score
and the minimisation variables being included as covari-
ates. The results will be reported as an adjusted mean dif-
ference in SCL-20D score with its corresponding 95%
confidence interval.
Economic analyses
The economic analyses will examine the cost-effectiveness
of the complex intervention from an NHS perspective.
Resource usage will be collected in the trial in relation to
primary health care, community health and secondary
health care services. These data will be collected from
questionnaires administered to patients at each follow up
point. The questionnaires will be designed for this study
and will be based on questionnaires used in economic
evaluations of other interventions.
Unit cost estimates, from routine published sources such
as PSSRU Unit Costs of Health and Social Care [13], will
then be applied to resource use data collected above to
generate patient level cost estimates which will be pre-
sented as a mean cost with a measure of uncertainty. EQ-
5D data will facilitate estimation of health-related quality
of life, which will be expressed in terms of health states
within the 245-state classification and in terms of health
state values based on the preferences of a sample of the
UK public [14]. Mean utility for each treatment allocation
will be estimated with a measure of uncertainty. The anal-
yses above will enable the estimation of mean differences
in costs and effects for the treatment and control alloca-
tions. These will be presented with 95% confidence inter-
vals around the differences in costs and effects.
Uncertainty will be represented using the cost effective-
ness acceptability curve (CEAC), a graphical representa-
tion of the probability of an intervention being cost-
effective [15].
Approvals and Sponsorship
SMaRT Oncology-2 has been approved, with favourable
assessments at all sites (ref: 08/S11ADMIN/49; 08/S0701/
63), by the Scotland A Research Ethics Committee (ref:
08/MRE00/23). Management approval has been granted
by the Research and Development Offices of NHS Lothian
and NHS Greater Glasgow.
The trial is co-sponsored by the University of Edinburgh
and NHS Lothian Health Board.
Timescales
Recruitment commenced May 2008. The target for recruit-
ment closure is June 2010, with outcome data collection
continuing until June 2011.
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